Genthon, Alexis Brissot, Eolia Malard, Florent van de Wyngaert, Zoe Bonnin, Agnès Banet, Anne Marjanovic, Zora Ikhlef, Souhila Lapusan, Simona Sestili, Simona
...
Published in
Clinical lymphoma, myeloma & leukemia
More than one-third of patients with acute myeloid leukemia (AML) will relapse after allogenic hematopoietic cell transplant (allo-HCT). The main challenge is to overcome disease resistance to achieve a new complete remission while avoiding excessive toxicity. Gemtuzumab ozogamicin (GO), a conjugate of calicheamicin linked to the humanized monoclon...
Bostan, Hayri Toptas, Tayfur Tanrikulu, Funda Pepedil Kut, Kevser Arikan, Fatma Yilmaz, Fergun Atagunduz, Isik Firatli-Tuglular, Tulin
Published in
Clinical lymphoma, myeloma & leukemia
With the advent of tyrosine kinase inhibitors (TKIs), patients with chronic myeloid leukemia (CML) have a life expectancy similar to those of age- and gender-matched healthy populations. Nevertheless, patients receiving TKIs report chronic adverse events such as fatigue, edema, and muscle cramps, which lead to a decrease in their quality of life (Q...
Martino, Massimo Pitino, Annalisa Tripepi, Giovanni Paviglianiti, Annalisa Russo, Letteria Cusumano, Giuseppa Rossetti, Antonio Provenzano, Pasquale Fabio Porto, Gaetana Meliambro, Nicola
...
Published in
Clinical lymphoma, myeloma & leukemia
The application of different models of autologous stem-cell transplantation (ASCT) in multiple myeloma has demonstrated the feasibility and safety of outpatient-based programs of care. Although several systematic reviews have evaluated the burden of caregivers, only a few studies have included outpatient ASCT. The feelings of lack of family support...
Kambhampati, Swetha Hunter, Bradley Varnavski, Andrei Fakhri, Bita Kaplan, Lawrence Ai, Weiyun Z Pampaloni, Miguel Huang, Chiung-Yu Martin, Thomas 3rd Damon, Lloyd
...
Published in
Clinical lymphoma, myeloma & leukemia
More than one-half of high-risk patients with relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) relapse after autologous hematopoietic cell transplantation (auto-HCT). In this phase II study, we investigate the long-term outcomes of high-risk patients with rrDLBCL receiving intensive consolidation therapy (ICT) with OVA (ofatumumab, et...
Orlandi, Erika Iorio, Giuseppe Carlo Bartoncini, Sara Gallio, Elena Cavallo, Federica Santoro, Federica Ricardi, Umberto Levis, Mario
Published in
Clinical lymphoma, myeloma & leukemia
Post-transplant lymphoproliferative disorder (PTLD) is an aggressive malignancy that occurs in patients who have undergone solid organ transplantation or hematopoietic stem cell transplantation. It develops as the result of uncontrolled cell proliferations owing to reduced immunological surveillance. PTLD may occur with a various spectrum of clinic...
Wang, Yu Lu, Aidong Jia, Yueping Zuo, Yingxi Zhang, Leping
Published in
Clinical lymphoma, myeloma & leukemia
Acute megakaryoblastic leukemia (AMKL) is a biologically heterogeneous subtype of acute myeloid leukemia that originates from megakaryocytes. Patients with AMKL with non-Down syndrome (DS) had a poorer prognosis. However, clear prognostic indicators and treatment recommendations for this subgroup remain controversial. Herein, we performed a retrosp...
Gupta, Tejpal Manjali, Jifmi Jose Kannan, Sadhana Purandare, Nilendu Rangarajan, Venkatesh
Published in
Clinical lymphoma, myeloma & leukemia
The extent of staging required to evaluate for systemic involvement in patients with primary central nervous system lymphoma (PCNSL) remains controversial. Eligible studies reporting on diagnostic yield of extensive systemic staging, including pre-treatment whole-body 18F-fluoro-deoxy-glocose positron emission tomography with or without computed to...
Hu, Guan-Hua Lu, Ai-Dong Jia, Yue-Ping Zuo, Ying-Xi Wu, Jun Zhang, Le-Ping
Published in
Clinical lymphoma, myeloma & leukemia
The impact of extramedullary infiltration (EMI) on the clinical outcomes of pediatric patients with acute myeloid leukemia (AML) are controversial. A total of 214 pediatric patients with low-risk AML were classified as having EMI (central nervous leukemia [CNSL] and/or myeloid sarcoma [MS]) and not having EMI. Patients with isolated MS before AML d...
Meyers, Sydney Henning, Chace Swift, Regina Eades, Benjamin Spektor, Tanya M Berenson, James R
Published in
Clinical lymphoma, myeloma & leukemia
Zhao, Jin Su, Liping Zhong, Jinghua
Published in
Clinical lymphoma, myeloma & leukemia
The purpose of this study was to assess the risk factors for cancer-specific mortality and cardiovascular mortality in patients with diffuse large B-cell lymphoma (DLBCL). A retrospective cohort study involving patients with DLBCL who were registered in the Surveillance, Epidemiology, and End Results (SEER) database was performed. The risk factors ...
